Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

FDA

FDA

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • FDA
  • News

Vir Biotechnology Shares Move Lower; Co, WuXi Biologics Terminate A Greater China Collaboration Agreement For Antibodies Including VIR-7831

By Benzinga Newsdesk
Today, 4:29 PM
As previously disclosed, Vir Biotechnology, Inc. (the “Company”) and WuXi Biologics (Hong Kong) Limited (“WuXi Bio”) entered into a Development and Manufacturing Collaboration Agreement dated

VIR

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News

FDA Approves Regeneron and Sanofi’s Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

By Ragothaman Srinivasan
Today, 4:08 PM
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

REGN

Read More
5 minute read
  • FDA
  • News

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data In Two Oral Presentations At The 59th European Renal Association Congress

By Benzinga Newsdesk
Today, 4:06 PM
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress Atacicept is the first known investigational therapy to decrease both

VERA

Read More
4 minute read
  • Biotech
  • FDA
  • General
  • News

Regeneron, Sanofi Report FDA Approved Dupixent As Treatment For Adults, Children Aged 12+ With Esophagitis

By Benzinga Newsdesk
Today, 3:16 PM
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly

REGN

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Global
  • News
  • Rumors

World Health Organization Confirms Will Convene A Meeting On Monkeypox Friday

By Benzinga Newsdesk
Today, 11:52 AM
-Reuters

AEMD

Read More
1 minute read
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Why TherapeuticsMD Shares Are Trading Higher Today

By Vandana Singh
Today, 10:52 AM
TherapeuticsMD Inc (NASDAQ:TXMD) shares are trading higher after FDA approved the supplemental application, including minor revisions to Annovera’s in vitro release testing…

TXMD

Read More
7 minute read
  • FDA
  • News

Chinook Therapeutics Presents Data From Atrasentan Phase 2 AFFINITY IgA Nephropathy Patient Cohort And Evotec Collaboration At The 59th European Renal Association Congress 2022

By Benzinga Newsdesk
Today, 10:33 AM
Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022 The AFFINITY IgAN cohort of

KDNY

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • News

Trinity Biotech Announces CE Mark Of Its 10-Minute Covid-19 Antigen Test

By Benzinga Newsdesk
Today, 9:21 AM
Trinity Biotech plc (NASDAQ:TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test. This CE mark allows for use by healthcare professionals and trained users. The Company intends to launch the test

TRIB

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Immix Biopharma Highlights Its IMX-110 Showed Improved Survival Over J&J’s Janssen’s FDA-Approved Drug Trabectedin Related To Connective Tissue Cancer Soft Tissue Sarcoma

By Benzinga Newsdesk
Today, 8:48 AM
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) In a connective tissue cancer Soft Tissue

IMMX

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Insider Trades
  • Large Cap
  • News
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn’s Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara

By Vandana Singh
Today, 8:20 AM
Here's a roundup of top developments in the biotech space over the last 24 hours:

APRE

Posts navigation

1 2 … 417 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service